Influenza Vaccine: 2 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused influenza vaccine: all 8 decisive outcomes across 2 agencies were positive or positive with restrictions.
PHARMAC (New Zealand) has been easier on influenza vaccine than on its own caseload: it refused 0 of 7 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 13.2 years separate the first record, 9 May 2013 at PHARMAC (New Zealand), from the most recent, 2026 at PBAC (Australia).
Coverage is thin among the largest agencies: 6 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and AWMSG (Wales) among them — hold no record for influenza vaccine at all.
Not every gap is a refusal: for influenza vaccine, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 14 records date from 2023 or later.
3 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 8 years in total.
2 of the 2 agencies here assessed influenza vaccine more than once, PHARMAC (New Zealand) most often at 11 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 2 of the 18 agencies here have assessed influenza vaccine.
The full ledger for influenza vaccine reads 8 recommended, 3 other, 2 advice and 1 withdrawn.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Prevention of influenza | Not applicable | source |
| PHARMAC (New Zealand) | 31 Jan 2025 | Individuals aged 0 to 59 months | PTAC advice: High · decision reached | source |
| PHARMAC (New Zealand) | 3 Oct 2022 | Maori and Pacific people, 50 to 64 years of age | PTAC advice: No Formal Recommendation | source |
| PHARMAC (New Zealand) | 30 Sep 2022 | Options for widened access - Open listing | PTAC advice: High | source |
| PHARMAC (New Zealand) | 30 Sep 2022 | People over 50 years of age -widen access | PTAC advice: No Formal Recommendation | source |
9 further decisions for influenza vaccine, across 2 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- ipilimumab / nivolumab — also decided by PHARMAC in 2025Q1
- desogestrel — also decided by PHARMAC in 2025Q1
- daratumumab — also decided by PHARMAC in 2025Q1
- rituximab — also decided by PHARMAC in 2025Q1
- ruxolitinib — also decided by PHARMAC in 2025Q1
- dostarlimab — also decided by PHARMAC in 2025Q1
Coverage: 14 decisions for influenza vaccine from 2 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class J07B — Vaccines. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.